KCPG
ONCE

Kavar Capital Partners Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Kavar Capital Partners Group’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$8K – 438
2018
Q2 		$8K Hold
100
– – ﹤0.01% 339
2018
Q1 		$7K Buy
+100
New +$5.78K ﹤0.01% 352

Other funds holding ONCE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Kavar Capital Partners Group's ONCE Position: Q3 2018 in Review

Kavar Capital Partners Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2018, closing a stake of 100 shares — an estimated $8K sold.

Kavar Capital Partners Group first reported a position in ONCE in Q1 2018 and held it in 2 quarters. The position peaked at $8K in Q2 2018. 176 funds tracked by Wall St. Rank hold ONCE as of Q3 2018.

  • Kavar Capital Partners Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Kavar Capital Partners Group sold 100 Spark Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $8K.
  • Kavar Capital Partners Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Kavar Capital Partners Group's Spark Therapeutics, Inc. Common Stock position peaked at $8K in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Kavar Capital Partners Group's 13F filing for Q3 2018, filed 9 Nov 2018.